Lynx Investment Advisory Neurocrine Biosciences Inc Transaction History
Lynx Investment Advisory
- $135 Billion
- Q2 2024
A detailed history of Lynx Investment Advisory transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Lynx Investment Advisory holds 22 shares of NBIX stock, worth $2,690. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22Holding current value
$2,690% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding NBIX
# of Institutions
641Shares Held
95.3MCall Options Held
661KPut Options Held
227K-
Black Rock Inc. New York, NY14.2MShares$1.74 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.23 Billion0.03% of portfolio
-
State Street Corp Boston, MA4.61MShares$564 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.47MShares$302 Million0.6% of portfolio
-
Jpmorgan Chase & CO New York, NY2.36MShares$289 Million0.03% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.7B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...